

## Research and Innovation Highlights

- 70 prospective and retrospective clinical studies in progress within the department.
- Six active head and neck cancer clinical trials with 6 more currently being negotiated through Rush University Cancer Center.
  - ECOG 3163 activated for advanced stage nasal and paranasal sinus squamous cell carcinoma for upfront standard of care surgery or 3 cycles of neoadjuvant chemotherapy with surgery followed by standard radiation +/- chemotherapy.
  - HN006 was activated to compare sentinel lymph node biopsy vs. neck dissection for patients with oral cancer.
- Six active clinical trials in rhinology, sleep surgery, and otology with 3 additional trials being negotiated within the department.
  - Sleep Surgery Division is participating in the national Inspire Adhere registry to track outcomes after hypoglossal implant surgery.
  - Rhinology and Skull Base Surgery Division is participating in the FDA clinical trials assessing efficacy of exhalational delivery device Xhance for management of chronic rhinosinusitis with or without polyps in adult and pediatric patients.
- 57 peer-review articles published in FY20.
- 34 peer-review articles published in FY21 to date.
- Departmental microbiome initiative launched in rhinology, laryngology, and sleep surgery in partnership with Allergy/Immunology under the leadership of Pete Batra, MD, and Maha Mahdavinia, MD.
- Precision medicine cancer initiative launched in partnership with Tempus for head and neck and skull base cancer in partnership with Tempus under the leadership of Samer Al-Khudari, MD, and Pete Papagiannopoulos, MD.
- Smartphone otoscope prototype developed to enhance telemedicine otologic care under the leadership of Ashok Jagasia, MD, and Mark Wiet, MD. The prototype is in the final stages of completion and will be presented at a national audiology conference in May 2021.
- Nanoparticle research involving noninvasive translocation of ototopical antibiotics in an in vitro model by Ashok Jagasia, MD.